- Home
- CLLS vs FCRS Comparison
CLLS vs FCRS Comparison
Compare CLLS & FCRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.69
Company Overview
Basic Information| Metric | CLLS | FCRS |
|---|---|---|
| Founded | 1999 | 2025 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.2M | 363.0M |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CLLS | FCRS |
|---|---|---|
| Price | $3.69 | $10.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 44.3K | ★ 147.3K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,551,000.00 | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | N/A |
| 52 Week Low | $1.10 | $10.04 |
| 52 Week High | $5.48 | $10.92 |
Technical Indicators
Market Signals| Indicator | CLLS | FCRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 38.49 |
| Support Level | $3.44 | $10.08 |
| Resistance Level | $3.98 | $10.34 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 20.28 | 11.54 |
Price Performance
Historical Comparison CLLS
FCRS
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About FCRS FutureCrest Acquisition Corp. Class A Ordinary Shares
FutureCrest Acquisition Corp is a blank check company.